At present, there are two main therapeutic applications of radiopharmaceuticals labelled with 177Lu: the treatment of metastatic neuroendocrine tumours with the use of somatostatin receptors, and the treatment of metastatic castration-resistant prostate cancer with the use of PSMA-targeting ligands [3]. The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.